Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NCT03127098 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT03127098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03127098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Lead sponsor
NantCell, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
June 26, 2017
Completion date
December 7, 2017
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colon cancer, lung cancer, ovarian cancer, pancreatic cancer, thyroid cancer